News

Filter

Boehringer Ingelheim gets Breakthrough designation for leukemia candidate

17-09-2013

German pharma major Boehringer Ingelheim has gained Breakthrough Therapy Designation from the US Food…

Boehringer IngelheimEuropeOncologyPharmaceuticalRegulationvolasertib

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline

02-08-2013

German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

Boehringer Ingelheim starts pivotal trial of volasertib in AML

01-03-2013

German family-owned drug major Boehringer Ingelheim has started a Phase III trial of its polo-like kinase…

Boehringer IngelheimOncologyPharmaceuticalResearchvolasertib

Analysts view Boehringer Ingelheim's first move into cancer drug market

11-10-2012

German family-owned drug major Boehringer Ingelheim last month announced the submission of a Marketing…

afatinibBoehringer IngelheimMarkets & MarketingnintedanibOncologyPharmaceuticalResearchvolasertib

COMPANY SPOTLIGHT

Menarini

Back to top